Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved by the Food and Drug Administration (FDA) in November 2023 as the first of its kind.

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities seek newer information on vaccine results in the global fight against chikungunya.